Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

BACKGROUND: The lenvatinib (LEN) plus everolimus (EVE) combination demonstrated improved progression-free survival over everolimus alone in a phase 2 trial (Study-205). OBJECTIVE: To compare quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) between LEN + EVE and EVE...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chung-Han, Wan, Yin, Smith, Alan, Xie, Ran, Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Kidney Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385286/
https://www.ncbi.nlm.nih.gov/pubmed/34467233
http://dx.doi.org/10.1016/j.euros.2021.06.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385286/
https://www.ncbi.nlm.nih.gov/pubmed/34467233
http://dx.doi.org/10.1016/j.euros.2021.06.008

Ejemplares similares